DDAVP induces systemic release of urokinase-type plasminogen activator

Thromb Haemost. 1989 Sep 29;62(2):686-9.

Abstract

The desamino-d-arginine vasopressin (DDAVP) induced enhancement of endogenous fibrinolysis is generally attributed to the release of tissue-type plasminogen activator (t-PA) from the vessel wall. The observation of concurrent release of urokinase-type plasminogen activator (u-PA), which eventually might cooperate in the enhanced fibrinolytic activity, has not been reported thus far. In a preliminary study in two healthy human volunteers we found a 1.8-fold increase of urokinase-antigen (UK-antigen) and a 1.7-fold increase of plasmin-activatable pro-urokinase (pro-UK) activity to DDAVP intravenously. The plasma-peak levels coincided with the maximal t-PA level. These responses following infusion of DDAVP were subsequently confirmed in a randomized double blind cross-over study in six human volunteers. We conclude that u-PA is released by DDAVP concurrently with t-PA and that it is presumably from the same origin as t-PA i.e. endothelial cells. u-PA and t-PA may therefore cooperate in the enhanced fibrinolytic activity upon DDAVP infusion.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Deamino Arginine Vasopressin / pharmacology*
  • Double-Blind Method
  • Fibrinolytic Agents / metabolism*
  • Humans
  • Pilot Projects
  • Plasminogen Activators / metabolism*
  • Random Allocation
  • Urokinase-Type Plasminogen Activator / metabolism*

Substances

  • Fibrinolytic Agents
  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator
  • Deamino Arginine Vasopressin